Published in Cancer Weekly, February 8th, 2005
Under the terms of the agreement, Serenex will utilize its Proteome Mining technology to elucidate the mechanism-of-action targets and generate broad selectivity information for compounds that GSK is developing.
The agreement allows GSK scientists worldwide from any therapeutic area and stage of discovery to submit compounds to Serenex for profiling against specific tissues and cell lines. The use of Serenex's technology is aimed at enabling GSK to determine the best compounds to take forward into later stage pre-clinical and clinical development.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.